Abstract
Background Duchenne muscular dystrophy (DMD) is caused by DMD mutations leading to dystrophin loss. Full length Dp427 is the primary dystrophin isoform expressed in skeletal muscle and is also expressed in the central nervous system (CNS). Two shorter isoforms, Dp140 and Dp71, are highly expressed in the CNS. While a role for Dp140 and Dp71 on DMD CNS co-morbidities is well known, relationships between lack of Dp140 and Dp71 and DMD motor outcomes are not. We have conducted a series of investigations addressing this.
Methods Functional outcome data from 387 DMD boys aged 4.0-15.4 years was subdivided by DMD mutation expected effect on isoform expression; Group 1 (Dp427 absent, Dp140/Dp71 present, n=201); group 2 (Dp427/Dp140 absent, Dp71 present, n=152); and group 3 (Dp427/Dp140/Dp71 absent, n=34). Relationships between isoform group and North Star ambulatory assessment (NSAA) scores, 10m walk/run and rise times were explored using regression analysis. We used Capillary Western immunoassay (Wes) analysis to study Dp427, Dp140 and Dp71 production in wild-type and DMD skeletal muscle and myogenic cultures. Grip strength was studied in wild-type, mdx (Dp427 absent, Dp140/Dp71 present), mdx52 (Dp427/Dp140 absent, Dp71 present) and DMD-null (lacking all isoforms) mice.
Results In DMD boys, we found a strong association between isoform group and motor function. In DMD boys, mean NSAA scores at 5 years of age were 6.1 points lower in group 3 than group 1 (p<0.01) and 4.9 points lower in group 3 than group 2 (p=0.05). Mean peak NSAA scores were 4.0 points lower in group 3 than group 1 (p<0.01), 2.4 points lower in group 3 than group 2 (p=0.09) and 1.6 points lower in group 2 than group 1 (p=0.04).
Average grip strength in peak force at 3 months of age was higher in mdx than mdx52 mice (p=0.01).
Dp427, but not Dp71, was produced in normal skeletal muscle; low levels of Dp71 were detected in DMD skeletal muscle. High Dp71 levels were present in wild-type and DMD myogenic cultures.
Conclusions DMD boys lacking Dp140 and Dp140/Dp71 displayed worse motor function with a cumulative effect of isoform loss. DMD mouse models lacking Dp427 and Dp140 had lower grip strength than those lacking Dp427 but not Dp140. Our results highlight the importance of considering the effects of dystrophin isoform loss on DMD motor impairment, with important implications for understanding the complex relationship between brain and muscle function in DMD and patient stratification for clinical trials.
Competing Interest Statement
Mary Chesshyre, Deborah Ridout, Kate Maresh, Lianne Abbott, Vandana Ayyar Gupta, Marion Main, Yoko Ookubo, Yasumasa Hashimoto and Silvia Torelli report no financial disclosures or potential conflicts of interest. Yoshitsugu Aoki is the grant holder of the grant Grants in Aid for Research on Nervous and Mental Disorders (grant number 2 to 6) Kate Maresh has received payments to her institution from Great Ormond Street Hospital Childrens Charity and MRC Centre for Neuromuscular Diseases, Queen Square, London in the last 36 months. Valeria Ricotti is co founder, EVP and CMO of DiNAQOR, shareholder of Solid Biosciences Adnan Manzur is the clinical lead for the North Star clinical network and is one of the co grant holders from the MDUK for maintenance of the network. Mariacristina Scoto has received speaker and consultancy honoraria For Roche, Avexis, Santhera and Biogen Giovanni Baranello has received consultancy honoraria from AveXis, Roche, Biogen, PTC, and Sarepta Therapeutics. Dr Giovanni Baranello has received speaker honoraria from AveXis, Roche and PTC Francesco Muntoni is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre and has received speaker and consultancy honoraria from Sarepta Therapeutics, Avexis, PTC Therapeutics, Roche and Pfizer.
Funding Statement
We are grateful to Muscular Dystrophy UK (MDUK) for funding the North Star network and Certus Technology Associates Limited for hosting the database. The North Star DMD Network is supported by a grant from Muscular Dystrophy UK to Dr Adnan Manzur and Prof Francesco Muntoni, at UCL. The support of Association Francaise contre les Myopathies for the Outcome measures in Duchenne Muscular Dystrophy: A Natural History Study: Imaging and Neuropsychology Sub-study is gratefully acknowledged. The support of Great Ormond Street Hospital Childrens Charity for A Study of Emotional Function in Duchenne Muscular Dystrophy (EmoDe Study) is gratefully acknowledged. Kate Maresh was supported by the Medical Research Council (MRC) via the MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London. The support of Great Ormond Street Hospital Childrens Charity and the NIHR GOSH biomedical research centre (BRC) for the Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations study is gratefully acknowledged. This work is supported by the NIHR GOSH BRC. The views expressed are participants of the author(s) and not necessarily participants of the NHS, the NIHR or the Department of Health. The support of EUH2020 grant 83245 Brain Involvement iN Dystrophinopathies is also gratefully acknowledged. The support of the grant Grants in Aid for Research on Nervous and Mental Disorders (grant number 2 to 6 to Yoshitsugu Aoki) for the functional testing using dystrophic and wild-type mice is gratefully acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North Star clinical network study was reviewed by the North Sheffield Research Ethics Committee and it was felt that it did not need to go to a research ethics committee. Written informed consent was obtained for the collection of all clinical data and the NorthStar clinical network project has Caldicott Guardian approval. All clinical assessments are conducted according to the principles of the Declaration of Helsinki (2000) and its later amendments and the Principles of Good Clinical Practice. Tissue sampling was approved by the NHS national Research Ethics Service as follows under the studies Setting up of a rare diseases biological samples bank (biobank) for research to facilitate pharmacological, gene and cell therapy trials in neuromuscular disorders (NMD) (REC reference number: 06/Q0406/33 - Hammersmith and Queen Charlottes and Chelsea Research Ethics Committee, The use of cells as a model system to study pathogenesis and therapeutic strategies for Neuromuscular Disorders (REC reference 13/LO/1826 - London - Stanmore Research Ethics Committee) and Genes and Proteins in Neuromuscular Disorders (REC reference 13/LO/1894 - London - Camberwell St Giles Research Ethics Committee). Animal studies were performed in accordance with the appropriate ethics committee and have therefore been performed with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, [FM], upon reasonable request.
